Characteristics of the patients with SpA. Values are n (%) unless otherwise specified.
| Characteristics | Total | PsA | AS |
|---|---|---|---|
| Demographic features | |||
| Total no. patients included | 156 | 92 | 64 |
| Male/female | 107/49 (68/32) | 50/42 (54/46) | 57/7 (89/11) |
| Age, yrs, mean ± SD | 52 ± 13 | 55 ± 14 | 51 ± 12 |
| Disease duration, yrs, mean ± SD | 17 ± 11 | 15 ± 11 | 19 ± 12 |
| Diagnosis | |||
| PsA | 92 (59) | 92 (100) | — |
| AS | 64 (41) | — | 64 (100) |
| Treatment | |||
| Patients receiving biologic DMARD | 98 (63) | 50 (54) | 48 (75) |
| Patients not receiving biologic DMARD | 58 (37) | 48 (52) | 16 (25) |
| Methotrexate | 60 (38) | 54 (58) | 6 (9) |
| Cyclosporine | 18 (11) | 18 (19) | 0 (0) |
| Leflunomide | 9 (5) | 9 (9) | 0 (0) |
SpA: spondyloarthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; DMARD: disease-modifying antirheumatic drugs.